<DOC>
	<DOCNO>NCT01623544</DOCNO>
	<brief_summary>The objective study compare real-world effectiveness BFC FSC asthma patient new ICS/LABA combination therapy population U.S. health plan enrollees .</brief_summary>
	<brief_title>Asthma Comparative Effectiveness Study</brief_title>
	<detailed_description>A U.S. retrospective database analysis evaluate comparative effectiveness budesonide/formoterol fluticasone propionate/salmeterol among asthma patient</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>Continuous health plan enrollment 12 month index Rx At least two prescription fill BFC FSC within 12 month Asthma claim diagnosis , 12 64 year age time first prescription Evidence COPD Claims diagnosis inflammatory diseases cancer Presence Rx one type ICS/LABA combination index date Chronic steroid use Xolair use prior ICS/LABA index treatment</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Comparative Effectiveness</keyword>
	<keyword>Symbicort</keyword>
</DOC>